Información del artículo
Artículo
Opciones para acceder a los textos completos de la publicación Revista Clínica Española
Socio
Si es usted socio de FESEMI siga los siguientes pasos:
Diríjase desde aquí a la web de la >>>https://www.fesemi.org/publicaciones/revista-clinica/noticias<<< e inicie sesión mediante el formulario que se encuentra en la barra superior, pulsando sobre el candado.
Deslice el cursor hacia abajo hasta la sección "PUBLICACIONES" y pinche en "Revista Clínica Española":
>>>https://www.fesemi.org/publicaciones/revista-clinica/noticias<<<
Comprar
References
[1]
H. Lu, C.W. Stratton, Y.W. Tang.
Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle.
J Med Virol., 92 (2020), pp. 401-402
[2]
D. Wang, B. Hu, C. Hu, F. Zhu, X. Liu, J. Zhang, et al.
Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China.
JAMA., 323 (2020), pp. 1061-1069
[3]
L. Mao, H. Jin, M. Wang, Y. Hu, S. Chen, Q. He, et al.
Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China.
JAMA. Neurol., 77 (2020), pp. 683-690
[4]
G. Toscano, F. Palmerini, S. Ravaglia, L. Ruiz, P. Invernizzi, M.G. Cuzzoni, et al.
Guillain-Barré syndrome associated with SARS-CoV-2.
N Engl J Med., 382 (2020), pp. 2574-2576
[5]
Z. Li, X. Li, J. Shen, M.T.V. Chan, W.K.K. Wu.
Miller Fisher syndrome associated with COVID-19: an up-to-date systematic review.
Environ Sci Pollut Res Int., 28 (2021), pp. 20939-20944
[6]
H. Lee, H.J. Kim, Y.J. Choe, J.Y. Shin.
Signals and trends of Guillain-Barré syndrome after the introduction of live-attenuated vaccines for influenza in the US and South Korean adverse event reporting systems.
Vaccine., 38 (2020), pp. 5464-5473
[7]
S. Waheed, A. Bayas, F. Hindi, Z. Rizvi, P.S. Espinosa.
Neurological complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 vaccine.
Cureus., 13 (2021),
[8]
S.U. Patel, R. Khurram, A. Lakhani, B. Quirk.
Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1.
BMJ Case Rep., 14 (2021),
[9]
E.F. Wijdicks, C.J. Klein.
Guillain-Barré syndrome.
Mayo Clin Proc., 92 (2017), pp. 467-479
[10]
A. Alshekhlee, Z. Hussain, B. Sultan, B. Katirji.
Guillain-Barré syndrome: incidence and mortality rates in US hospitals.
Neurology., 70 (2008), pp. 1608-1613
[11]
C. Fokke, B. van den Berg, J. Drenthen, C. Walgaard, P.A. van Doorn, B.C. Jacobs.
Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria.
Brain., 137 (2014), pp. 33-43
[12]
A.M. Márquez Loza, K.B. Holroyd, S.A. Johnson, D.M. Pilgrim, A.A. Amato.
Guillain-Barré syndrome in the placebo and active arms of a COVID-19 vaccine clinical trial: temporal associations do not imply causality.
Neurology., (2021),
[13]
O. Ogbebor, H. Seth, Z. Min, N. Bhanot.
Guillain-Barré syndrome following the first dose of SARS-CoV-2 vaccine: a temporal occurrence, not a causal association.
IDCases., 24 (2021),
